Headlines about Mediwound (NASDAQ:MDWD) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mediwound earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.9560381827378 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Mediwound from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a report on Wednesday, October 4th. ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. Oppenheimer set a $10.00 target price on shares of Mediwound and gave the stock a “buy” rating in a report on Tuesday, October 17th. Cowen assumed coverage on shares of Mediwound in a report on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price on the stock. Finally, Jefferies Group reissued a “buy” rating and set a $10.00 target price on shares of Mediwound in a report on Thursday, September 28th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $9.13.

Shares of Mediwound (NASDAQ:MDWD) opened at $4.40 on Friday. Mediwound has a 12 month low of $4.15 and a 12 month high of $8.25. The company has a market cap of $120.36, a price-to-earnings ratio of -4.49 and a beta of -0.01.

Mediwound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, November 16th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%. equities analysts predict that Mediwound will post -1.06 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/19/mediwound-mdwd-receives-coverage-optimism-score-of-0-03.html.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Insider Buying and Selling by Quarter for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.